Albert Robichaud - 19 Oct 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Scientific Officer
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Albert Robichaud
Issuer symbol: SAGE
Transactions as of: 19 Oct 2021
Net transactions value: -$44,964
Form type: 4
Filing time: 21 Oct 2021, 16:03:51 UTC
Previous filing: 17 Jun 2021
Next filing: 15 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Award	$0	+3,800	+2.7%	$0.000000	143,735	19 Oct 2021	Direct	F1, F2
transaction	SAGE	Common Stock	Tax liability	$44,964	-1,116	-0.78%	$40.29	142,619	19 Oct 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 3,800 shares.
F2	Reflects beneficial ownership balance which includes 284 shares purchased on June 30, 2021 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.